Navigation Links
Lehner-Utrata Forceps

ProductsLehner-Utrata Forceps
Company Bausch & Lomb Storz
Item Lehner-Utrata Forceps
Features 
Description Utrata-like fine angled tips with gently curved shaft for performing capsulorhexis through tunnel incisions. Dull finish. Round handle manufactured in titanium.
Info Bausch & Lomb Storz
Customer Service: (585) 338-6000
Web site: http://www.storz.com/

Related medicine products :

1. Lehner-Utrata Capsulorhexis Forceps
2. Ostrum Antrum Punch Forceps
3. Storz Antrum Punch Forceps
4. Sidebiting Antrum Punch Forceps
5. Pediatric Ostrum Antrum Punch Forceps
6. Rotating Ostrum Antrum Punch Forceps
7. Pediatric Rotating Ostrum Antrum Punch Forceps
8. McPherson Straight Bipolar Forceps
9. McCullough Bipolar Forceps
10. Bipolar Coaptation Forceps
11. Jeweler Type Bipolar Insulated Forceps
...ly invasive surgery is founded on superior medical...-Chip cameras, 1-Chip cameras, Light sources, Coup...nding needs., ,Superior resolution and color repr...meras, and are the benchmark by which all other me...
...ra System provides easy-to-use features, auto iris...amera head construction is based on Solos durable ...era System, International (GS9900-PAL) includes: ,...rd and video cables , (GS 9905) Camera head with 3...
Provides a combination of concentrated cold / hot and compression for the elbow
Provides extended cold therapy for acute, chronic, or post-surgical applications. Cryotherapy can reduce pain, swelling and speed recovery.
Medicine Products:
(Date:10/13/2008)...eading Content Rights Management System, Supports... Content Spend, WEST CHESTER, Pa., Oct. 13 /PRNew...ding global pharmaceutical manufacturer has integr...primary platform for the,secure distribution, data...cs for their new product video content. Imperium i...
(Date:10/13/2008)...swire/ -- The National Coalition for,Quality Color...ncerns over,the National CT Colonography Study pub...Medicine. The evidence must be closely evaluated, ...y is not without significant,potential risks. The ...py,remains the "Gold Standard" for colorectal canc...
(Date:10/13/2008)...blem in daily life, survey shows, PORTLAND, Ore.,...three-quarters of people living with psoriasis say...e, according to a National Psoriasis,Foundation 20...viduals with psoriasis and psoriatic arthritis,als...ly lives, shapes their,feelings about themselves a...
(Date:10/13/2008)...swire/ -- During the Pri-Med New York,conference a...are providers,took a 20-question quiz prepared by ...n Somerset, NJ. The quiz tested basic knowledge of..., EMR software, and healthcare,administration., T... The average number,of correct answers was only 7....
Breaking Medicine News(10 mins):Health News:Global Pharma Integrates Imperium(TM) to Support Launch Content ROI Initiatives! 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 3Health News:National Psoriasis Foundation Releases 2008 Study Results 2Health News:MTBC Practice Management Quiz Sends Message to Doctors: There is Real Room for Improvement or a Need to Outsource 2
...eld at the Grampians Community Health Centre has m...r drugs //. Educating people about the adverse e...arried out by the GCH center. Problems related t...amilial and community factors all in some way happ...
Drug - resistant microbes raise concerns
...rds and Primary Health Organisations, (PHOs), whic...en resolved //, with both parties reaching an agr... visits. An estimated 680,000 New Zealanders who ... 45 - 64 years, are expected to benefit from July ...
... reported that two tourists have contracted malari... that the recent outbreak //of malaria on the isla...ndustry. The tourists, a Canadian and an American...fter visiting Great Exuma. The Public Health Agen...
Other Medicine News:Health News:Drug - resistant microbes raise concerns 2Health News:Outbreak of Malaria to Lead to Loss in Tourist Industry 2
(Date:10/8/2008)...nolimumab Program to be Discontinued and Headcount...lts of its Portfolio Review; Zanolimumab Program ... Number of Employees... Genmab A/S (OMX: GEN),announced today that it is ...4(R)). In addition, as a result of a portfolio rev...
(Date:10/8/2008)...inical program to evaluate TAXUS(R) Element(TM) Pl...ent, NATICK, Mass., Oct. 8 /PRNewswire-FirstCall/...day announced that it has completed enrollment in,...y,s third-generation,TAXUS(R) Element(TM) paclitax...ogram has enrolled nearly 1,500 patients at 100 U....
(Date:10/8/2008)...France, Oct. 8 /- Vical Incorporated ...ical data and new nonclinical data,demonstrating t...adly,applicable in DNA- and protein-based infectio...nes. Alain P. Rolland, Pharm.D., Ph.D., Vical,s,Se...resent the data today,Wednesday, October 8, at th...
(Date:10/7/2008)...EGO, Oct. 7 /- Prometheus Laboratorie...announced findings from its,development of PROMETH...st,for irritable bowel syndrome (IBS). The finding... of particular biomarkers in blood samples,between...hese biomarkers,combined with a proprietary algor...
Breaking Medicine Technology:Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 2Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 3Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 4Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 2Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 3Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 2Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 3Exclusion of common bile duct stones prior to gallstone operations 5081 1Exclusion of common bile duct stones prior to gallstone operations 5081 2UCLA Tokyo University nanobiotechnology symposium at UCLA to highlight advances in nanomedicine 5078 1UCLA Tokyo University nanobiotechnology symposium at UCLA to highlight advances in nanomedicine 5078 2Gamma interferon could aid fight against fungal infections 1046 1Gamma interferon could aid fight against fungal infections 1046 2Polyanalgesic Consensus Panels New Treatment Guidelines Via Intraspinal Infusion for Severe Chronic Pain 5074 1Polyanalgesic Consensus Panels New Treatment Guidelines Via Intraspinal Infusion for Severe Chronic Pain 5074 2Polyanalgesic Consensus Panels New Treatment Guidelines Via Intraspinal Infusion for Severe Chronic Pain 5074 3Polyanalgesic Consensus Panels New Treatment Guidelines Via Intraspinal Infusion for Severe Chronic Pain 5074 4Polyanalgesic Consensus Panels New Treatment Guidelines Via Intraspinal Infusion for Severe Chronic Pain 5074 5
...One Month Study in Seventy Type 2 Diabetes Patient...hnologies Inc.,(TSX:CJB) today announced positiv...le-dose clinical study for the treatment of Type 2...(TM):Exendin-4.,Results from the study demonstra... tolerated and, when administered once-weekly at e...
...VERLY, Mass.--(BUSINESS WIRE)--Mar 27, 2007 - Inot... presentation of,positive Phase 2 clinical data de...potential for INO-1001 as a preventative agent for...ed in subjects,with acute ST-elevated myocardial i...coronary intervention. The presentation was,made i...
Other Medicine Technology:PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results,Demonstrate Safety and Efficacy at Once-Weekly Dosing 2PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results,Demonstrate Safety and Efficacy at Once-Weekly Dosing 3PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results,Demonstrate Safety and Efficacy at Once-Weekly Dosing 4Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical,Data for INO-1001 at ACC Demonstrating PARP Inhibition and,Anti-inflammatory Activity in Plasma of Patients Undergoing Primary,Percutaneous Coronary Intervention 2Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical,Data for INO-1001 at ACC Demonstrating PARP Inhibition and,Anti-inflammatory Activity in Plasma of Patients Undergoing Primary,Percutaneous Coronary Intervention 3Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical,Data for INO-1001 at ACC Demonstrating PARP Inhibition and,Anti-inflammatory Activity in Plasma of Patients Undergoing Primary,Percutaneous Coronary Intervention 4